Pablo Conesa‐Zamora

Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma

José García‐Solano, Miguel Pérez‐Guillermo, Pablo Conesa‐Zamora et al. · Human Pathology · 2010 · 119 citations

Full Recognition, Surgical Oncology, Colorectal Surgery +10

MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9

Petra Vychytilova‐Faltejskova, Jana Merhautová, Táňa Macháčková et al. · Oncogenesis · 2017 · 101 citations · Full text

Medicine, Egfr Ligand Epiregulin, Pathology +13

Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn’s disease and ulcerative colitis

Diana Lacruz-Guzmán, Daniel Torres‐Moreno, Francisco Pedrero et al. · European Journal of Clinical Pharmacology · 2012 · 93 citations

Inflammation, Chronic Inflammatory Diseases, Allergy +11

Effect of Human Papillomavirus on Cell Cycle–Related Proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in Precursor Lesions of Cervical Carcinoma

Pablo Conesa‐Zamora, Asunción Doménech-Peris, Francisco Javier Orantes-Casado et al. · American Journal of Clinical Pathology · 2009 · 82 citations · Full text

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis

María José Morales-Lara, Juan D. Cañete, Daniel Torres‐Moreno et al. · Joint Bone Spine · 2012 · 66 citations

Inflammation, Rheumatology, Anti-tnf Therapies +12